Assessment of minimal residual disease in acute myeloid leukemia
D Grimwade, P Vyas, S Freeman - Current opinion in oncology, 2010 - journals.lww.com
D Grimwade, P Vyas, S Freeman
Current opinion in oncology, 2010•journals.lww.comSensitive MRD detection using MFC and/or RQ-PCR has become feasible in virtually all
AML patients. MRD monitoring is now considered a standard of care in APL. Recent studies
provide a strong rationale for prospective trials investigating the merits of extending MRD
detection to alter therapy and potentially improve outcome in other AML subtypes.
AML patients. MRD monitoring is now considered a standard of care in APL. Recent studies
provide a strong rationale for prospective trials investigating the merits of extending MRD
detection to alter therapy and potentially improve outcome in other AML subtypes.
Summary
Sensitive MRD detection using MFC and/or RQ-PCR has become feasible in virtually all AML patients. MRD monitoring is now considered a standard of care in APL. Recent studies provide a strong rationale for prospective trials investigating the merits of extending MRD detection to alter therapy and potentially improve outcome in other AML subtypes.
Lippincott Williams & Wilkins